Eupraxia Pharmaceuticals (EPRX) Short term Debt (2022)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Short term Debt of $10.3 million for Q4 2023, up 12914.69% year-over-year from N/an in Q4 2022, and up 12914.69% quarter-over-quarter from $79418.0 in Q4 2022.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Short term Debt (2022) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Short term Debt for 2 consecutive years, with $10.3 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Short term Debt rose 12914.69% year-over-year to $10.3 million; the TTM figure through Dec 2023 stood at $10.3 million (up 12914.69% YoY), while the FY2023 annual figure was $10.3 million, up 12914.69% from the prior year.
- Short term Debt grew to $10.3 million in Q4 2023 per EPRX's latest filing, from $79418.0 in the prior quarter.
- Across five years, Short term Debt topped out at $10.3 million in Q4 2023 and bottomed at $79418.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 305.07 Mn | 305.07 Mn | - |